MANILA, Philippines (AP) — A shooting at a high school in the southern Philippines on Friday left two 14-year-old students and the teenage gunman dead and wounded at least eight people, local government and police officials said.
The shooting at Banga National High School in the South Cotabato town of Banga is under investigation, the Philippine National Police said in a statement. Police officers secured the campus and coordinated with school officials and medical responders, the statement said.
South Cotabato Governor Reynaldo Tamayo said the two students killed were a boy and a girl, both 14. He said the gunman also shot himself and died.
Banga Mayor Albert Palencia told DZBB radio that the gunman hit 10 students in the classroom next to his, two of whom died while eight were wounded. A person who was hyperventilating was also brought to a hospital, according to the governor.
Tamayo said the gunman's best friend told officials that the teenager was a member of an online "true crimes community." Authorities were investigating the account and whether it had any connection to the shooting, he said.

#students #south

For much of 2025, UnitedHealth Group (UNH) looked like a company under siege as higher medical costs and weaker margins rattled investors. UNH stock sold off sharply, and questions emerged around the company's earnings outlook as well as the health of its long-standing growth story.
That picture is starting to improve in 2026. UnitedHealth's latest results showed a clear turnaround in profitability as it generated $112 billion in revenue and $8 billion in earnings from operations. Management also raised the company's full-year adjusted EPS outlook to a range of $19.50 to $20 and increased its operating cash flow forecast to about $24 billion. Those moves suggest UnitedHealth sees its recovery as more than a short-term earnings rebound.
This High-Yield Construction Stock Just Raised Its Dividend by 40%
Dear Intuit Stock Fans, Mark Your Calendars for September 17
This Dividend Stock Is Beating the Market in 2026 and Yields 2.36%

#Stock #billion #Dividend #management

With a market cap of $18.8 billion, Zimmer Biomet Holdings, Inc. (ZBH) is a global medical technology company specializing in musculoskeletal healthcare solutions. The company designs, manufactures, and markets products ranging from orthopedic reconstructive implants to sports medicine, spine, craniomaxillofacial, and thoracic solutions.
Companies worth more than $10 billion are generally labeled as "large-cap" stocks and Zimmer Biomet fits this criterion perfectly. Its innovations support surgeons and healthcare providers worldwide in treating disorders and injuries of bones, joints, and soft tissues.
Billionaire Charlie Munger, Who Died at 99, Skipped Insurance on His Mansion Since He Could Just Write a Check to Rebuild — 'All Intelligent People Do It My Way'
Why It's Time to Load Up on Nvidia Stock
The Case for Selling CrowdStrike Stock

#Stock

Parnassus Investments, an investment management company, released the "Parnassus Growth Equity Fund" second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (net of fees), outperforming the Russell 1000 Growth Index's 16.74%. Holdings in Information Technology and Consumer Discretionary sectors boosted relative returns, while Communication Services and Financials holdings detracted. For the year-to-date period, the Fund returned 6.17% (net of fees), outperforming the Russell 1000 Growth's 5.33%. The firm remains constructively bullish on U.S. equities and continues to be selective, valuation-sensitive, and focused on disruptive growth opportunities through active stock selection. Growth stocks advanced during the second quarter, as the Russell 1000 Growth Index generated strong double-digit returns driven by increased confidence in the durability of the ongoing artificial intelligence (AI) infrastructure build-out. Additionally, reviewing the Fund's top five holdings could help identify its best picks for 2026.
In its second-quarter 2026 investor letter, Parnassus Growth Equity Fund highlighted Medline Inc. (NASDAQ:MDLN). Medline Inc. (NASDAQ:MDLN) manufactures med-surg products serving hospitals, surgery centers, physician offices, post-acute facilities, and nursing home sites of care. On September 15, 2026, Medline Inc. (NASDAQ:MDLN) closed at $36.59 per share. Over the past month, Medline Inc. (NASDAQ:MDLN) declined 4.23%, and YTD its shares lost 22.68%. Medline Inc. has a market capitalization of $42.22 billion.
Parnassus Growth Equity Fund stated the following regarding Medline Inc. (NASDAQ:MDLN) in its Q2 2026 investor letter:
"Medline Inc. (NASDAQ:MDLN) shares declined as medical technology stocks broadly came under pressure. The company also faced near term concerns surrounding tariffs and higher transportation costs, though we remain confident in its long-term competitive positioning."
Medline Inc. (NASDAQ:MDLN) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 52 hedge fund portfolios held Medline Inc. (NASDAQ:MDLN) at the end of the second quarter which was 65 in the previous quarter. While we acknowledge the potential of Medline Inc. (NASDAQ:MDLN) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

#medline #NASDAQ #fund #parnassus

Oscar Health (OSCR) raised its full-year earnings outlook while lowering its expected medical costs to cover benefits for its nearly 3 million Affordable Care Act exchange members. OSCR stock climbed in early Wednesday stock market action ahead of its 9 a.m. ET investor conference.
Oscar, which made an aggressive play to gain ACA market share, has seen enrollment surge 47% from a year ago as of June 30, even as overall enrollment has plunged due to the expiration of enhanced premium subsidies. As of now, it looks like the bet is paying off in a big way, with shares up 126% this year through Tuesday. But it's still a bit early to know, because Oscar's earnings depend not only on its own members' costs, but also those of other ACA insurers.
The ACA's No. 2 insurer by membership behind Centene (CNC) said that it now expects its medical loss ratio, or benefit costs as a share of premiums, to be in the 81% to 82% range, down from the prior outlook of 81.5% to 82.5%.
Oscar boosted its outlook for earnings from operations by $100 million at both ends to a range of $600 million to $800 million. The unchanged revenue outlook, between $18.7 billion and $19 billion, implies that no additional customer churn is expected.
Here is what investors should keep in mind. Compared to the overall ACA risk pool, Oscar's enrollment is relatively young, healthy and more likely to sign up for very-high-deductible bronze plans. Yet based on its relatively healthy risk pool, Oscar expects about 20% of its premiums will be paid out via risk adjustment to other carriers under ACA rules. That means results in the second half of this year depend to a large degree on the level of healthcare utilization by non-Oscar members. As of now, it's a bit early to tell, since healthcare spending tends to rise as the year progresses and insured members exhaust their deductibles.

#oscar #year

Exton, Pennsylvania-based West Pharmaceutical Services, Inc. (WST) designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products. Valued at $25.7 billion by market cap, the company's technologies include the design and manufacture of packaging components, research and development of drug delivery systems, and contract laboratory services and other services.
Companies worth $10 billion or more are generally described as "large-cap stocks," and WST perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the medical instruments & supplies industry. WST stands out as a market leader with a diversified portfolio serving pharma and healthcare.
Billionaire Charlie Munger, Who Died at 99, Skipped Insurance on His Mansion Since He Could Just Write a Check to Rebuild — 'All Intelligent People Do It My Way'
Nvidia CEO Jensen Huang Just Dropped Huge News for This Cybersecurity Stock
How to Play GME Stock as GameStop CEO Ryan Cohen Buys $20.3 Million in Shares

#Stock #billion

Cardinal Health, Inc. (CAH), headquartered in Dublin, Ohio, operates as a healthcare services and products company. Valued at $54.6 billion by market cap, the company's services include pharmaceutical distribution, health-care product manufacturing, distribution and consulting services, drug delivery systems development, pharmaceutical packaging, automated dispensing systems manufacturing, and retail pharmacy franchising.
Companies worth $10 billion or more are generally described as "large-cap stocks," and CAH perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the medical distribution industry. As one of the top three U.S. pharma wholesalers, CAH holds a commanding market position. Its diversified pharmaceutical and medical distribution portfolio, broadens its customer base, adds resilience to market swings, and creates multiple revenue streams with cross-selling opportunities.
Billionaire Charlie Munger, Who Died at 99, Skipped Insurance on His Mansion Since He Could Just Write a Check to Rebuild — 'All Intelligent People Do It My Way'
Nvidia CEO Jensen Huang Just Dropped Huge News for This Cybersecurity Stock
How to Play GME Stock as GameStop CEO Ryan Cohen Buys $20.3 Million in Shares

#market #Health #Manufacturing #systems

ResMed (RMD) shares are pushing higher on Tuesday after a senior RBC Capital Markets ****** yst upgraded the medical equipment specialist to an "Outperform" rating. In his research note, Craig Wong-Pan cited RMD's robust Q4 performance as he lifted his price target as well to $262, indicating potential upside of nearly 10% from here.
Note that ResMed stock has already been in a massive uptrend in recent months, currently trading about 28% above its June low.
Goldman Sachs Expects Fed Chair Kevin Warsh to Raise Rates This Week — But Not Because of Oil Prices.
Billionaire Charlie Munger, Who Died at 99, Skipped Insurance on His Mansion Since He Could Just Write a Check to Rebuild — 'All Intelligent People Do It My Way'
1 'Strong Buy' Dividend Stock Offering a 6.3% Yield Right Now

#markets

Apollo Global Management, Inc. (NYSE:APO) is reportedly in talks to acquire Johnson & Johnson (NYSE:JNJ) DePuy Synthes orthopedics business in a transaction that could value the unit at close to $20 billion, according to Bloomberg, as reported by Reuters. J&J generated $9.3 billion of revenue from the orthopedics business in 2025, making the potential transaction material for both companies. The discussions could reach an agreement within weeks, although J&J is also considering a public-market spin-off. This is consistent with J&J's October 2025 decision to separate DePuy Synthes within an expected 18-to-24-month timeframe and shift its MedTech portfolio toward higher-growth, higher-margin businesses.
For Apollo Global Management, Inc. (NYSE:APO), the attraction is the opportunity to acquire a large, established medical-device franchise with substantial recurring demand from joint-replacement and surgical procedures. A roughly $20 billion valuation against $9.3 billion of 2025 revenue implies a price-to-sales multiple of about 2.2x, giving Apollo room to pursue operational improvements, portfolio rationalization, and margin expansion if the business is acquired at an attractive valuation.
DePuy Synthes also has meaningful scale and leading positions across major orthopedics categories, while J&J has recently invested in technologies that could strengthen the franchise, including an agreement covering Gemtrack tracking technology for robotic and navigation-assisted joint procedures and the acquisition of Expanding Innovations for expandable spine implants. Apollo is also entering the potential deal from a position of considerable financial scale: it had approximately $1.05 trillion of ***** ets under management as of June 30, 2026, with $198 billion in equity strategies and $849 billion in credit strategies. Its second-quarter results included $111 billion of gross capital deployment, demonstrating the capacity to execute large transactions.
For Johnson & Johnson (NYSE:JNJ), a sale could accelerate the portfolio transformation that management has already identified as a strategic priority while potentially delivering a sizeable upfront cash inflow. J&J explicitly said its planned orthopedics separation should increase the company's top-line growth and operating margins by allowing it to concentrate on Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision.
The company has also been restructuring orthopedics, with $307 million of restructuring expense in 2025, following $167 million in 2024 and $319 million in 2023, primarily tied to market and product exits. A sale could therefore remove a business that has required restructuring resources while allowing J&J to redeploy capital toward areas it views as higher growth and higher margin.

#billion #depuy

Wednesday’s Senate confirmation hearing wasn’t the first time much of the American public met Dr. Nicole Saphier and heard her perspective; President Donald Trump’s nominee for US surgeon general is a health and wellness influencer who has amassed hundreds of thousands of followers through her podcast and social media platforms.
In some ways, the surgeon general position – often referred to as the nation’s doctor – is the original health influencer, tasked with translating science into terms that are easy to understand and guiding the public on ways to improve their health.
“For a decade, I have specialized in translating complex, fast-evolving medical information on various media platforms into content that millions of Americans can understand and use, including during the uncertainty of the global pandemic,” Saphier, a radiologist and Fox News contributor, said in Wednesday’s hearing.
“I realized then how badly this country needs public health communication that is straightforward and grounded in the best evidence available,” she said. “My years of communicating directly with the public have prepared me to explain complex topics in a way that they can understand.”
But experts say that social media has changed how people receive health information, with increasingly blurred lines as to who is considered to have authority and expertise – and that bringing an influencer into the role of surgeon general presents both opportunities and challenges.

#public #saphier #hearing

White House chief of staff Susie Wiles is "cancer free," she announced on X on Sept. 16, 2026. "Some personal news I'm grateful to share. After a medical appointment at the Mayo Clinic this week, my pathology results came back clear," she explained.

Wiles was diagnosed with early-stage breast cancer in March and told the New York Times that her prognosis was "strong." Wiles did not disclose at the time what treatment she would undergo, but said it would last several weeks — during which time she planned to continue working. Noting that one in eight American women develops breast cancer at some point in their lives, Wiles posted on X at the time: "Every day, these women continue to raise their families, go to work and serve their communities with strength and determination. I now join their ranks."
A breast cancer diagnosis is life-altering, but Wiles's comments highlighted the progress that's been made in recent years. Breast cancer is now detected at Stage 0 or 1 — before it has spread — in the majority of cases. Survival rates have risen dramatically, but "the treatments we use to treat early-stage breast cancer have become more tailored" and less disruptive to women's lives, Dr. Lynn Dengel, a University of Virginia surgical oncologist, told Yahoo in March.
"Because [Wiles] was taking care of her health [and getting screened], not only will her prognosis be better, but it will probably minimize what treatment she has to go through and will benefit her work-life and overall balance," Dengel said. She added that most of her patients are diagnosed early and can continue to work while undergoing breast cancer treatment, reducing the financial burden and overall disruption to their lives.
Wiles was diagnosed at age 68 — slightly older than the median age (62) when most women learn they have breast cancer. More than 380,000 American women are diagnosed with some form of breast cancer each year, according to the American Cancer Society (ACS).
Breast cancer remains the most common form of cancer among women in the U.S., except for skin cancers. And rates are rising. But there's good news: More women are surviving the disease. Treatments have also improved, becoming tolerable enough that many women still work, as Wiles intends to do. Here's what to know about the disease, why rates are rising and how women can reduce their risks.

#breast #diagnosed

Apollo Global Management, Inc. (NYSE:APO) is reportedly in talks to acquire Johnson & Johnson (NYSE:JNJ) DePuy Synthes orthopedics business in a transaction that could value the unit at close to $20 billion, according to Bloomberg, as reported by Reuters. J&J generated $9.3 billion of revenue from the orthopedics business in 2025, making the potential transaction material for both companies. The discussions could reach an agreement within weeks, although J&J is also considering a public-market spin-off. This is consistent with J&J's October 2025 decision to separate DePuy Synthes within an expected 18-to-24-month timeframe and shift its MedTech portfolio toward higher-growth, higher-margin businesses.
For Apollo Global Management, Inc. (NYSE:APO), the attraction is the opportunity to acquire a large, established medical-device franchise with substantial recurring demand from joint-replacement and surgical procedures. A roughly $20 billion valuation against $9.3 billion of 2025 revenue implies a price-to-sales multiple of about 2.2x, giving Apollo room to pursue operational improvements, portfolio rationalization, and margin expansion if the business is acquired at an attractive valuation.
DePuy Synthes also has meaningful scale and leading positions across major orthopedics categories, while J&J has recently invested in technologies that could strengthen the franchise, including an agreement covering Gemtrack tracking technology for robotic and navigation-assisted joint procedures and the acquisition of Expanding Innovations for expandable spine implants. Apollo is also entering the potential deal from a position of considerable financial scale: it had approximately $1.05 trillion of **** ets under management as of June 30, 2026, with $198 billion in equity strategies and $849 billion in credit strategies. Its second-quarter results included $111 billion of gross capital deployment, demonstrating the capacity to execute large transactions.
For Johnson & Johnson (NYSE:JNJ), a sale could accelerate the portfolio transformation that management has already identified as a strategic priority while potentially delivering a sizeable upfront cash inflow. J&J explicitly said its planned orthopedics separation should increase the company's top-line growth and operating margins by allowing it to concentrate on Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision.
The company has also been restructuring orthopedics, with $307 million of restructuring expense in 2025, following $167 million in 2024 and $319 million in 2023, primarily tied to market and product exits. A sale could therefore remove a business that has required restructuring resources while allowing J&J to redeploy capital toward areas it views as higher growth and higher margin.

#NYSE #johnson

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.

Top 5 Upgrades:
Wells Fargo upgraded Ulta Beauty (ULTA) to Equal Weight from Underweight with a price target of $525, up from $450, after meeting with management. The firm says the company is navigating industry headwinds better than expected.
Oppenheimer upgraded Etsy (ETSY) to Outperform from Perform with a $90 price target. The firm cites the company's AI search benefits, product improvements, and app engagement for the upgrade.
Berenberg upgraded Eli Lilly (LLY) to Buy from Hold with a price target of $1,400, up from $1,220. The firm says its 2026 return on investment **** ysis confirms Eli Lilly's "strong track record of delivering best-in-class returns on investment."
Bernstein upgraded Agilon Health (AGL) to Outperform from Market Perform with a price target of $125, up from $86. The company is undergoing a turnaround focused on risk-taking discipline and incremental medical cost improvements, the firm tells investors in a research note.

#firm #outperform #perform

Prosper Stars & Stripes, a long/short equity fund, recently released its second-quarter 2026 investor letter. The letter can be downloaded here. In Q2 2026, the portfolio delivered a strong net return of +30.1% compared to the Russell 2000 Index's +21.5% return and the HFRX Equity Hedge Index's +10.3% return. The long book drove performance, generating a 43.2% gross contribution, while average net exposure remained relatively modest at 47%. U.S. economic growth remained resilient despite inflation concerns, elevated energy prices, and geopolitical uncertainty. Markets rallied sharply after easing U.S.-Iran tensions pushed oil prices lower, supporting renewed risk appetite. Small-cap equities benefited significantly, with Information Technology, Industrials, and Health Care leading gains, while Energy declined as crude prices fell. Year to date, the Composite returned +23.7%, slightly ahead of the Russell 2000's +22.6% and well above the HFRI Equity Hedge Index's +9.7%. Additionally, you can review the Portfolio's top 5 holdings to see its best picks for 2026.
In its second-quarter 2026 investor letter, Prosper Stars & Stripes highlighted Vishay Precision Group, Inc. (NYSE:VPG). Headquartered in Malvern, Pennsylvania, Vishay Precision Group, Inc. (NYSE:VPG) specializes in precision measurement and sensing technologies. On September 14, 2026, Vishay Precision Group, Inc. (NYSE:VPG) closed at $60.49 per share. Over the past month, Vishay Precision Group, Inc. (NYSE:VPG) declined 10.77%, while its shares gained 85.95% over the past 52 weeks. Vishay Precision Group, Inc. (NYSE:VPG) has a market capitalization of $805.75 million, and its shares traded within a 52-week range of $28.71 and $151.78.
Prosper Stars & Stripes stated the following regarding Vishay Precision Group, Inc. (NYSE:VPG) in its Q2 2026 investor letter:
"Vishay Precision Group, Inc. (NYSE:VPG) was the largest contributor to our long book during the second quarter of 2026. Vishay's core technologies, bulk metal foil resistors and bonded foil strain gauges, are niche, designed-in sensor solutions embedded in precision instruments, such as semiconductor test equipment and aerospace, medical, military, and robotics applications. Vishay has done a lot of work during the industrial downturn to improve its footprint to have more profitable growth as the industrial economy recovers after years of tepid performance. In addition, Vishay is pursuing a substantial secular growth opportunity in humanoid robotics, with $500 to $1,200 in content per robot. Management is executing on both sides of the ledger: cutting costs while strengthening the leadership bench with new Chief Operating Officer and Chief Product Officer roles. Together, these initiatives are expected to lift gross margins and EBITDA margins from 39% and 8% in 2025 toward long-term targets of 46% and 20% over the next several years. We reduced and then exited our position in Vishay during the quarter but still see good value in th

Oregon billionaires Phil and Penny Knight committed $1.1 billion to the Providence St. Vincent Medical Center and the Providence Heart Institute to build Oregon's first hospital dedicated to women's health, the medical center announced Tuesday.
Phil Knight, co-founder of Nike, and his wife, have supported the institute for more than a decade, previously giving it more than $200 million, including a $75 million gift earlier this year. Along with creating the new women's hospital, their new donation will help the medical center expand cardiovascular care and clinical research and training programs for the heart institute's medical personnel. It will also make it easier to integrate patient care across the medical center.
"Women's health needs change throughout life, and too often patients are asked to navigate multiple specialties and care settings on their own," Ray Moreno, the medical center's CEO, said in a statement. "The Knights' gift is an opportunity to bring these resources together, expanding access for women across Oregon and creating a strong foundation to bridge care gaps in women's health."
The donation is particularly significant because it comes at a moment when U.S. hospitals are seeing far more pregnant patients who are also managing chronic health conditions like diabetes, hypertension, addiction, and behavioral and mental health issues. It also lands at the same time healthcare organizations are struggling with the impact of government funding cuts.
"Resources are scarce, and healthcare is increasingly looking to philanthropy to fill in the gaps," Dan Oseran, the heart institute's executive medical director, told the Chronicle. "A gift like this reduces that friction a little bit and provides the ability to do things we wouldn't otherwise be able to do."

#center #oregon #knight #providence

Parnassus Investments, an investment management company, released the "Parnassus Growth Equity Fund" second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (net of fees), outperforming the Russell 1000 Growth Index's 16.74%. Holdings in Information Technology and Consumer Discretionary sectors boosted relative returns, while Communication Services and Financials holdings detracted. For the year-to-date period, the Fund returned 6.17% (net of fees), outperforming the Russell 1000 Growth's 5.33%. The firm remains constructively bullish on U.S. equities and continues to be selective, valuation-sensitive, and focused on disruptive growth opportunities through active stock selection. Growth stocks advanced during the second quarter, as the Russell 1000 Growth Index generated strong double-digit returns driven by increased confidence in the durability of the ongoing artificial intelligence (AI) infrastructure build-out. Additionally, reviewing the Fund's top five holdings could help identify its best picks for 2026.
In its second-quarter 2026 investor letter, Parnassus Growth Equity Fund highlighted Revolution Medicines, Inc. (NASDAQ:RVMD) as a new addition. Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company that develops novel targeted therapies for RAS-addicted cancers. On September 15, 2026, Revolution Medicines, Inc. (NASDAQ:RVMD) closed at $204.86 per share. Over the past month, Revolution Medicines, Inc. (NASDAQ:RVMD) declined 6.53% and its shares gained 358.00% over the past 52 weeks. Revolution Medicines, Inc. (NASDAQ:RVMD) has a market capitalization of $43.91 billion.
Parnassus Growth Equity Fund stated the following regarding Revolution Medicines, Inc. (NASDAQ:RVMD) in its Q2 2026 investor letter:
"In the Health Care sector, we see compelling long-term idiosyncratic growth opportunities in drug discovery, diagnostics and medical innovation. During the quarter, we added Revolution Medicines, Inc. (NASDAQ:RVMD), developer of a promising new drug for pancreatic cancer. Revolution Medicines' lead drug candidate, daraxonrasib, has delivered strong late-stage clinical results in pancreatic cancer, with data suggesting it could become a new standard of care and support significant commercial potential, alongside additional opportunities in other cancers over time."
Revolution Medicines, Inc. (NASDAQ:RVMD) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 105 hedge fund portfolios held Revolution Medicines, Inc. (NASDAQ:RVMD) at the end of the second quarter, compared to 106 in the previous quarter. While we acknowledge the potential of Revolution Medicines, Inc. (NASDAQ:RVMD) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Tr

Parnassus Investments, an investment management company, released the "Parnassus Growth Equity Fund" second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (net of fees), outperforming the Russell 1000 Growth Index's 16.74%. Holdings in Information Technology and Consumer Discretionary sectors boosted relative returns, while Communication Services and Financials holdings detracted. For the year-to-date period, the Fund returned 6.17% (net of fees), outperforming the Russell 1000 Growth's 5.33%. The firm remains constructively bullish on U.S. equities and continues to be selective, valuation-sensitive, and focused on disruptive growth opportunities through active stock selection. Growth stocks advanced during the second quarter, as the Russell 1000 Growth Index generated strong double-digit returns driven by increased confidence in the durability of the ongoing artificial intelligence (AI) infrastructure build-out. Additionally, reviewing the Fund's top five holdings could help identify its best picks for 2026.
In its second-quarter 2026 investor letter, Parnassus Growth Equity Fund highlighted Medline Inc. (NASDAQ:MDLN). Medline Inc. (NASDAQ:MDLN) manufactures med-surg products serving hospitals, surgery centers, physician offices, post-acute facilities, and nursing home sites of care. On September 15, 2026, Medline Inc. (NASDAQ:MDLN) closed at $36.59 per share. Over the past month, Medline Inc. (NASDAQ:MDLN) declined 4.23%, and YTD its shares lost 22.68%. Medline Inc. has a market capitalization of $42.22 billion.
Parnassus Growth Equity Fund stated the following regarding Medline Inc. (NASDAQ:MDLN) in its Q2 2026 investor letter:
"Medline Inc. (NASDAQ:MDLN) shares declined as medical technology stocks broadly came under pressure. The company also faced near term concerns surrounding tariffs and higher transportation costs, though we remain confident in its long-term competitive positioning."
Medline Inc. (NASDAQ:MDLN) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 52 hedge fund portfolios held Medline Inc. (NASDAQ:MDLN) at the end of the second quarter which was 65 in the previous quarter. While we acknowledge the potential of Medline Inc. (NASDAQ:MDLN) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

#medline #fund

The New York City Health Department has ordered 10 cooling towers in the South Bronx, including one at Yankee Stadium, to be cleaned and disinfected after preliminary testing found the presence of Legionella bacteria as officials investigate a cluster. NBC News medical contributor Natalie Azar discusses how the test was conducted the possible threat level to attendees.

#stadium

A police response to reports of a man chasing a woman spiraled into a deadly confrontation when an unrelated knife-wielding man charged an officer through a crowded seaside park in California, chilling new bodycam video shows.
The tense encounter unfolded Aug. 22 as Santa Monica Police Department officers investigated a report of a man chasing a woman near the Broadway stairs, according to a newly released critical incident briefing.
The man killed in the confrontation was identified by the Los Angeles County Department of Medical Examiner as 44-year-old Michael Rodriguez.
Bodycam Shows Los Angeles County Deputy Stabbed Seconds After Arriving At Knife Attack
Bodycam video shows Michael Rodriguez approaching a Santa Monica police officer with a knife raised in Palisades Park Aug. 22, 2026.

#police #knife

Dispatch.com readers can vote for their favorite boys high school athletes of the week on their desktop, the Dispatch.com mobile web or Dispatch app once per hour by scrolling down to ballots listed below.
Deadline is 4 p.m. Friday, Sept. 18.
The Ohio State University Wexner Medical Center high school Athlete of the Week voting occurs each week during high school sports competition and recognizes athletes across all sports.
Last week's Athlete of the Week: Berlin's Ethan Litton voted Boys Athlete of the Week presented by Wexner Medical Center
If you can't see the ballot when you scroll to the bottom of this story, try refreshing the link or clearing the cache in your browser. You do not have to be a subscriber to vote.

#wexner #medical

Hyrox, the popular indoor fitness competition, is adjusting its policies and procedures after a world champion was allowed to continue at a competition in China last weekend despite suffering fecal incontinence.
Joanna Wietrzyk was competing in the age 16-24 elite event in Beijing on Saturday when she suddenly became ill. But despite fecal matter running down her legs, Wietrzyk was allowed to keep competing. The Australian continued on and ended up winning the race in a time of 1:01.23.
But in the days since, Hyrox has received heavy criticism for allowing Wietrzyk to continue competing despite the potential health risks. The company said that, despite having "clear biocontaminant and medical procedures in place," the situation "blurred" protocols and created "ambiguity in how they were applied and understood."
"I apologize to all that were directly or indirectly affected, as well as to everyone who felt like we did not handle the situation like we should have," Hyrox co-founder Moritz Furste said in a statement. "Hyrox made a mistake by not reacting immediately during the race. In the end, it is my job to foresee these potential incidents — and I did not.
"Of course, we started improving event processes, plus making rulebook changes immediately. As of this moment, there are new rules and procedures in place to prevent situations like this from happening again."

#allowed

The Jacksonville Jaguars received a scare involving one of their most important offensive players during Sunday's NFL Week 1 win over the Cleveland Browns. Brian Thomas Jr. left the game in the second quarter with a shoulder injury and initially was listed as questionable to return, creating immediate concern for a Jacksonville offense that had already jumped out to a big lead.
Fortunately, the latest update is much more encouraging than it initially appeared, and the Jaguars came away with a 34-10 victory over Cleveland.
MORE: 3 NFL teams that should be worried after Week 1
Jacksonville Jaguars wide receiver Brian Thomas Jr. (7) catches a pass during the first day of NFL Training Camp at the Miller Electric Center on Wednesday, July 29, 2026, in Jacksonville, Fla.
Thomas headed to the locker room with Jacksonville's medical staff after apparently injuring his shoulder. The Jaguars announced that he was questionable to return, and he had already made an impact before leaving, catching all three of his targets for 40 yards.

#cleveland

Army dentists say war games omit dental emergencies that could strain wartime casualty evacuation.
Broken equipment and limited supplies can hinder field dental training opportunities.
Forward dental teams can treat patients quickly and return them to duty.
A painful toothache or an oral infection might not sound like an injury that could sideline a soldier in combat, but US Army dental leaders warn that in a future conflict, such easily overlooked conditions could take troops out of the fight, consume scarce evacuation capacity, and further stress a strained medical system.
Most of the Army's major exercises don't include dental emergencies in their casualty scenarios, dentists said in a recent professional article, leaving commanders with an incomplete picture of the medical and triage or evacuation demands they could face in large-scale combat.

#evacuation #army #casualty #combat

A teenage girl has been arrested on charges including murder after Chicago police said she and several other people pushed a man off a moving transit train.
According to the Chicago Police Department, officers arrested a 15-year-old girl in connection to the Sept. 7 killing and confirmed that as of Sept. 14, two other suspects remained at large.
In a statement to USA TODAY, the Cook County Medical Examiner's Office identified the victim as Kyle T. Bickham.
Bickham, 29, died from multiple injuries due to a train striking a person, Meaghan Johnson, a spokesperson for the office, said. The medical examiner ruled Bickham's death a homicide.
Police said detectives arrested the 15-year-old girl on Sept. 11 after, according to a news release, she was identified as one of the suspects who allegedly "used force" to push Bickham from a moving CTA train.

#medical

Our ***** ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Achieved record quarterly revenue of $24 million, validating the long-term strategy of transitioning toward higher-value integrated systems and custom cabling solutions.
Realized significant operating leverage as revenue surpassed the $20 million threshold, driving adjusted EBITDA margins to 11.1%, exceeding the company's 10% long-term goal.
Diversification efforts successfully reduced reliance on traditional telecom, with meaningful contributions from aerospace, defense, industrial manufacturing, and medical imaging.
Unified engineering and product management teams into a single structure to accelerate product launches and ensure technical innovation translates directly to revenue impact.

#long #product

Brandi Glanville's health battle sparked an unexpected Bravo reunion, with Housewives stepping up financially. Several former co-stars donated to her GoFundMe after years of unexplained medical problems.
The fundraiser aimed to cover treatment costs linked to multiple diagnoses affecting Glanville. She admitted asking for help felt humiliating, but her medical expenses had pushed her toward crowdfunding.
TMZ reported that Glanville's GoFundMe had raised about $7,000 toward its $28,000 goal. Kyle Richards contributed $500, while Claudia Jordan and longtime friend James Maas each donated $100. Camille Grammer, who starred alongside Glanville on The Real Housewives of Beverly Hills, gave $200. She also explained why she decided to contribute despite their complicated history.
"I remember when she sent me flowers when I had my hysterectomy for uterine cancer," Grammer told TMZ. "I wanted to return the favor, and I feel bad for what she's going through." The pair had clashed during Real Housewives Ultimate Girls Trip in Morocco. Grammer acknowledged they were not particularly close, yet she still wanted to help.
Gina Rodriguez, another longtime friend, created the fundraiser earlier that week. She said doctors had discovered a fungal ball in Glanville's face that required removal. Glanville later discussed the fundraiser through her Brandi Glanville Unfiltered podcast. She broke down while describing the financial pressure surrounding her treatment.

#glanville #housewives #brandi #donated

Stanley Druckenmiller has quite a long and distinguished career as an investor. Much of this has to do with high-risk bets that have paid off enormously, such as when he and his boss, George Soros at Quantum Fund, shorted the U.K. pound for a handsome profit of what was reported to be around $1 billion.
For that reason, the trades Druckenmiller makes with his Duquesne family office matter, and his picks are taken seriously. One of the more intriguing ones is Duquesne's largest holding currently -- and for eight quarters now. It's not a famous name; rather, it's a next-generation healthcare diagnostics company that was once something of a sleeper. Here's a bit more about it.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
This huge bet on the future is Natera (NASDAQ: NTRA), a medical diagnostics company that uses unique, state-of-the-art technology to evaluate a patient's blood sample. Natera isn't the only business providing these liquid biopsies, as they're known, but its personalized, tumor-informed approach makes it a best-in-class screener in numerous use cases.
The major one is oncology, which is hardly surprising given the prevalence of cancer. Natera has a set of tests for this, led by Signatera, a highly personalized one constructed from the patient's tumor profile. With this, it detects circulating tumor DNA in the blood. To say this is useful in cancer detection is an understatement, so it's hardly surprising that Natera processed roughly 296,700 oncology tests in the company's second quarter. That was up a highly impressive 57% year over year.

#tumor

ATLANTA (AP) — Georgia Tech coach Brent Key said Jaylen Mbakwe was talking and responsive after a scary collision that had him stretchered off the field in the third quarter of the Yellow Jackets' 45-24 loss to No. 18 Tennessee on Saturday night.
Mbakwe collided head-first with Jordan Walker's knee. Walker was carried off the field, unable to put any weight on his leg. Mbakwe lay on the field and appeared motionless for several minutes before giving the crowd a thumbs-up while being stretchered off.
"Everything was moving when they moved him off the field. He was talking, responsive," Key said after the game. 'Obviously, I'm not going to speak anything medically about it, because I don't know."
The defensive back was taken by ambulance to Grady Hospital, located three miles from Georgia Tech's Bobby Dodd Stadium.
"As soon as I walk out of here, that's where I'm going — to check on my guy," Key said. "But he was talking, he was moving and whatnot when they carried him off. That's all I know at this point."

#field

Harold Bernstein, President of Research and Development and Chief Medical Officer at Maze Therapeutics, Inc. (NASDAQ:MAZE), sold 9,705 shares of common stock on September 4, 2026, according to an SEC Form 4 filing.
Metric
Value
Transaction value
~$255,000

#value #president #Research #medical

EAST LANSING — Michigan State coach Pat Fitzgerald thinks he may have his most important defensive player back for next week's game against Notre Dame.
In his postgame press conference after a 35-7 win over Eastern Michigan on Saturday, Sept. 12, Fitzgerald said that starting middle linebacker Jordan Hall was not cleared for the game by medical personnel but could be available for Week 3's rivalry game in South Bend.
"Jordan was really close playing today," Fitzgerald said. "Medical team told us that he was not cleared here late in the week. We made that decision collectively together to make sure that we think about his health, safety, and well-being. And I expect if we practice tomorrow that he'll be ready to go."
Hall made 88 tackles last season to lead Michigan State's defense and is a two-time captain. The senior made four tackles in 25 snaps in Week 1's win over Toledo but came on and off the field with a right elbow injury sustained on the second drive of the season. He walked into Spartan Stadium on Saturday with a brace on that right arm.
MSU LB Jordan Hall with a brace on his right elbow as he takes the Spartan Walk.

Saw him wince on a couple of handshakes. We’ll see how he looks in warmups.detroitnews pic.twitter.com/qklOKEfVbs

#game #spartan